Non-transferable risk: Difference between revisions

From ACT Wiki
Jump to navigationJump to search
imported>Doug Williamson
(Create the page. Source: MCT reading 4.1.3, p12, 01 March 2012.)
 
imported>Doug Williamson
(Add link.)
 
(5 intermediate revisions by the same user not shown)
Line 2: Line 2:




Non-transferable risks might be avoided or accepted and retained or reduced as appropriate. In the case of non-transferable business risks (which by definition are not avoided) it is important that the firm has a distinctive competence in the relevant areas.  
Non-transferable risks might be avoided or accepted and retained or reduced as appropriate.  
 
In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas.  


For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.
For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.
Line 9: Line 11:


== See also ==
== See also ==
*[[Transferable risk]]
* [[Committed risk]]
* [[Pharmaceuticals]]
* [[Risk management]]
* [[Transferable risk]]
* [[Uncommitted risk]]
 
[[Category:The_business_context]]
[[Category:Identify_and_assess_risks]]
[[Category:Manage_risks]]
[[Category:Risk_frameworks]]
[[Category:Risk_reporting]]

Latest revision as of 19:58, 2 July 2021

Non-transferable risks are risks which must be borne by an organisation.


Non-transferable risks might be avoided or accepted and retained or reduced as appropriate.

In the case of non-transferable business risks (which by definition are not avoided) it is important that the organisation has a distinctive competence in the relevant areas.

For example, a pharmaceutical company's non-transferable risks would include the risk that failure to gain approval for use of a new drug means that the research and development costs have been wasted.


See also